Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Odylia Therapeutics event brings together leaders across biotech, pharma, venture capital, patient advocacy, and research ...

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" ...

Commerce Secretary Lutnick discussed the state of the tariffs in the wake of President Trump’s comments on the pharmaceutical and electronics industries.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not ...

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...

Rahman discusses Google Gemini and what it could mean to the future of pharma commercialization and content development.